Custom Antibody Market

Custom Antibody Market by Service (Development, Purification, Labelling), Type (Monoclonal, Recombinant), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology), End User (Biopharma, CROs) & Region - Global Forecast to 2028

Report Code: BT 6817 Feb, 2023, by marketsandmarkets.com

Updated on : May 08, 2023

The global custom antibody market in terms of revenue was estimated to be worth $548 million in 2023 and is poised to reach $860 million by 2028, growing at a CAGR of 9.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Various elements such as rising research activities and funding investments for antibody developments, and the quality concerns over catalog antibodies & problems associated with them, are driving the market growth. However, the presence of alternatives to the antibodies is likely to hinder the growth of this market.

Attractive Opportunities in the Custom Antibody Market

Custom Antibody Market

To know about the assumptions considered for the study, Request for Free Sample Report

Custom Antibody Market Dynamics

DRIVER: Increased Funding is likely to upsurge the market growth

Antibody development and research has gained momentum, owing to the depleting mAbs pipeline, rising incidence of chronic and debilitating disorders such as cancer and infectious diseases; and growing need to develop effective and promising cures for several diseases that adversely affect the quality of life across the globe. The continuous rise in the funding for antibody research by government agencies is further supporting the growth of this market. For instance, in April 2022, Japan invested USD 970 million in regenerative medicine, focusing on induced pluripotent stem cells (iPS) to survive with the world's oldest population. The stem cells can then be used to repair human tissues or grow organs, indirectly impacting antibody research in the country. The funding will enable the country to continue to support custom antibody startups and SMEs, strengthen the emerging asiatic bioeconomy and help unlock the societal benefits of custom antibody.

RESTRAINT: Cost and complexities associated with antibody

The development of antibodies requires detailed knowledge and qualitative considerations, which require high capital investments and time limitations. In addition, the technologies required for antibody production include large bioreactors, filtration systems, and media & buffers for upstream/ downstream processing and purification. Thus, on average, the cost to produce custom mAbs goes on increasing depending on the additional services required, based on the procedures followed by each player. While developing the site-specific antibody requires consideration of the antigen against which antibodies need to be generated, followed by their specificity and reproducibility. Thus, the cost associated with antibodies can potentially hamper the market growth to a certain extent.

OPPORTUNITY: Emerging Markets

The rising investments by emerging countries in antibody drug discovery are responsible for the growth of the global market in the region. For instance, the Australian government has allocated USD 3.6 billion in basic research to support science, research, and innovation in the country from 2020 to 2021 to develop new products for treating lung conditions, including mepolizumab, a monoclonal antibody used to treat severe asthma. While the growing incidence of infectious and chronic disorders and increasing R&D initiatives to develop innovative treatment and diagnostic options are some of the factors likely to project the use of a custom antibody in the coming years. Additionally, developments in research infrastructure and the low-cost manufacturing advantage offered by emerging countries are expected to encourage market players to invest in emerging markets like Asia Pacific during the forecast period.

The antibody development segment dominated the custom antibody market in 2022.

Based on service, the market is broadly segmented into antibody development, antibody production & purification, and antibody labeling. In 2022, antibody development accounted for the dominant share of the global market. This segment's large share can be attributed to factors such as the rising incidence of cancer and other chronic diseases that are creating a high demand for therapeutic antibodies. Furthermore, key market players are investing in R&D in the market is likely to upsurge the growth of the segment.

The therapeutic applications segment of custom antibody market is expected to grow at the highest CAGR during the forecast period.

Based on application, the market is segmented into research and therapeutic applications. The therapeutic applications segment is expected to register the highest CAGR during the forecast period. Increased investment in the development of novel therapeutics through custom antibody is one of the factors driving the market growth. The need for fuel alternatives is increasing the adoption of custom antibody hence propelling the market growth.

Custom Antibody Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America dominated custom antibody market in 2022.

Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2021, North America accounted for the largest share in global market, followed by Europe and the Asia Pacific. The large share of the North American market is owing to various factors such presence of wide customer base and established distribution channels. Increased research funding for custom antibody is furthermore driving the market growth in North America.

Key players in the global market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies (US), Abcam plc. (UK), Cell Signaling Technology, Inc (US), Bio-Rad Laboratories, Inc (US), GenScript (China), and Rockland Immunochemicals, Inc (US).

Custom Antibody Market Report Scope

Report Metric

Details

Market Revenue in 2023

$548 million

Projected Revenue by 2028

$860 million

Revenue Rate

Poised to grow at a CAGR of 9.4%

Market Driver

Increased Funding is likely to upsurge the market growth

Market Opportunity

Emerging Markets

This report categorizes the custom antibody market to forecast revenue and analyze trends in each of the following submarkets:

By Service

  • Antibody Development
  • Antigen Preparation
  • Immunization & Hybridoma Production
  • Antibody Characterization
  • Antibody Production & Purification
  • Antibody Labeling

By Type

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Recombinant Antibodies
  • Others

By Source

  • Mice
  • Rabbit
  • Others

By Application

  • Research
  • Therapeutics

By Indication

  • Oncology
  • Infectious Diseases
  • Immunology
  • Neurobiology
  • Cardiovascular Diseases
  • Others

By End User

  • Pharmaceutical & Biotechnological Companies
  • Academic & Research Institutes
  • Contract Research Organisations

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments

  • In December 2022, Merck KGaA collaborated with Kelun-Biotech to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.
  • In October 2022, Thermo Fisher Scientific acquired The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics.
  • In July 2022, Bio-Techne acquired Namocell to expand its product portfolio, to include gene therapy development and commercialization, cell engineering, cell line development, single cell genomics, and antibody discovery.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 26)
    1.1 STUDY OBJECTIVES 
    1.2 CUSTOM ANTIBODY MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
           1.7.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 32)
    2.1 RESEARCH APPROACH 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 CUSTOM ANTIBODY MARKET: PRIMARY RESPONDENTS
    2.2 MARKET ESTIMATION METHODOLOGY 
           2.2.1 AVERAGE MARKET SIZE ESTIMATION (2022)
                    FIGURE 3 AVERAGE MARKET SIZE ESTIMATION (2022): GLOBAL MARKET
                    FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION METHODOLOGY
    2.3 DATA TRIANGULATION APPROACH 
          FIGURE 5 DATA TRIANGULATION METHODOLOGY
    2.4 GROWTH RATE ASSUMPTIONS 
    2.5 GROWTH FORECAST 
          FIGURE 6 GROWTH RATE ANALYSIS
    2.6 RISK ASSESSMENT 
    2.7 INSIGHTS FROM PRIMARY EXPERTS 
    2.8 GLOBAL CUSTOM ANTIBODY MARKET: RECESSION IMPACT 
          TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021–2027 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 42)
    FIGURE 7 GLOBAL CUSTOM ANTIBODY MARKET, BY SERVICE, 2023 VS. 2028
    FIGURE 8 GLOBAL MARKET SHARE, BY TYPE, 2023 VS. 2028
    FIGURE 9 GLOBAL MARKET SHARE, BY SOURCE, 2023 VS. 2028
    FIGURE 10 GLOBAL MARKET SHARE, BY APPLICATION, 2023 VS. 2028
    FIGURE 11 GLOBAL MARKET SHARE, BY INDICATION, 2023 VS. 2028
    FIGURE 12 GLOBAL MARKET SHARE, BY END USER, 2023 VS. 2028
    FIGURE 13 GLOBAL MARKET: GEOGRAPHICAL SNAPSHOT
 
4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 CUSTOM ANTIBODY MARKET OVERVIEW 
          FIGURE 14 RISING DEMAND FOR MONOCLONAL ANTIBODIES IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET
    4.2 NORTH AMERICA: MARKET SHARE, BY TYPE & COUNTRY (2022) 
          FIGURE 15 MONOCLONAL ANTIBODIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.3 GLOBAL MARKET SHARE, BY SOURCE (2022) 
          FIGURE 16 MICE SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.4 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 17 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 51)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 18 GLOBAL CUSTOM ANTIBODY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 4 GLOBAL MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Rising research activities and funding investments for antibody development
                    5.2.1.2 Growing use of custom antibodies in precision medicine
                    5.2.1.3 Use of antibodies in biomarker identification and validation
                    5.2.1.4 Quality concerns over catalog antibodies
           5.2.2 RESTRAINTS
                    5.2.2.1 High costs and complexities associated with antibody development
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging markets
                    5.2.3.2 Rising therapeutic applications for mAbs
                                FIGURE 19 NUMBER OF APPROVED ANTIBODY THERAPEUTICS (2016−2022)
           5.2.4 CHALLENGES
                    5.2.4.1 Challenges associated with immunization of host animals
                    5.2.4.2 Presence of alternative antibodies
    5.3 VALUE CHAIN ANALYSIS 
          FIGURE 20 GLOBAL MARKET: VALUE-CHAIN ANALYSIS
    5.4 ECOSYSTEM ANALYSIS 
          FIGURE 21 GLOBAL MARKET: ECOSYSTEM ANALYSIS
           5.4.1 ROLE IN ECOSYSTEM
    5.5 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 5 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.5.1 THREAT OF NEW ENTRANTS
           5.5.2 THREAT OF SUBSTITUTES
           5.5.3 BARGAINING POWER OF SUPPLIERS
           5.5.4 BARGAINING POWER OF BUYERS
           5.5.5 DEGREE OF COMPETITION
    5.6 PATENT ANALYSIS 
           FIGURE 22 GLOBAL MARKET: PATENT ANALYSIS
    5.7 PRICING ANALYSIS 
           5.7.1 AVERAGE SELLING PRICE TREND
           5.7.2 INDICATIVE PRICING ANALYSIS
                    TABLE 6 SELLING PRICE OF SERVICES PROVIDED BY GENSCRIPT
                    TABLE 7 SELLING PRICE OF SERVICES PROVIDED BY ABBIOTEC, INC.
           5.7.3 INDICATIVE PRICING ANALYSIS, BY REGION
                    TABLE 8 SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR INDIA
                    TABLE 9 SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR US
    5.8 TECHNOLOGICAL ANALYSIS 
           5.8.1 CUSTOM ANTIBODY SERVICES
    5.9 REGULATORY LANDSCAPE 
           5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 10 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.10 KEY CONFERENCES & EVENTS IN 2023 
           TABLE 11 GLOBAL MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 
           FIGURE 23 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON BUYING PROCESS
           FIGURE 24 GLOBAL MARKET: KEY BUYING CRITERIA FOR END USERS
    5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           FIGURE 25 REVENUE SHIFT AND NEW REVENUE
 
6 CUSTOM ANTIBODY MARKET, BY SERVICE (Page No. - 69)
    6.1 INTRODUCTION 
          TABLE 12 GLOBAL MARKET, BY SERVICE, 2021–2028 (USD MILLION)
    6.2 ANTIBODY DEVELOPMENT 
          TABLE 13 GLOBAL MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 14 GLOBAL MARKET FOR ANTIBODY DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION)
          TABLE 15 NORTH AMERICA: MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 16 EUROPE: MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 17 ASIA PACIFIC: MARKET FOR ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 18 LATIN AMERICA: MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.1 ANTIBODY CHARACTERIZATION
                    6.2.1.1 Crucial step in research & biopharmaceutical development for elimination of antibodies to drive market
                                TABLE 19 GLOBAL MARKET FOR ANTIBODY CHARACTERIZATION, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 20 NORTH AMERICA: MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 21 EUROPE: MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 22 ASIA PACIFIC: MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 23 LATIN AMERICA: MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.2 ANTIGEN PREPARATION
                    6.2.2.1 Development of research antibodies using bioinformatics tools to support market growth
                                TABLE 24 GLOBAL MARKET FOR ANTIGEN PREPARATION, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 25 NORTH AMERICA: MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 26 EUROPE: MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 27 ASIA PACIFIC: MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 28 LATIN AMERICA: MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.3 IMMUNIZATION & HYBRIDOMA PRODUCTION
                    6.2.3.1 Rising demand for therapeutic antibodies to drive market
                                TABLE 29 GLOBAL MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 30 NORTH AMERICA: MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 31 EUROPE: MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 32 ASIA PACIFIC: MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 33 LATIN AMERICA: MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 ANTIBODY PRODUCTION & PURIFICATION 
           6.3.1 RISING NEED FOR HIGH-QUALITY THERAPEUTICS TO DRIVE MARKET
                    TABLE 34 GLOBAL MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 35 NORTH AMERICA: MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 36 EUROPE: MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 37 ASIA PACIFIC: MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 38 LATIN AMERICA: MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 ANTIBODY FRAGMENTATION & LABELING 
           6.4.1 RISING NEED FOR SPECIFIC ANTIBODIES IN DETECTION OF NEW BIOMOLECULES TO SUPPORT MARKET GROWTH
                    TABLE 39 GLOBAL MARKET FOR ANTIBODY FRAGMENTATION & LABELING. BY REGION, 2021–2028 (USD MILLION)
                    TABLE 40 NORTH AMERICA: MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 41 EUROPE: MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 42 ASIA PACIFIC: MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 43 LATIN AMERICA: MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 CUSTOM ANTIBODY MARKET, BY TYPE (Page No. - 89)
    7.1 INTRODUCTION 
          TABLE 44 GLOBAL MARKET, BY TYPE, 2021–2028 (USD MILLION)
    7.2 MONOCLONAL ANTIBODIES 
           7.2.1 HIGH DEGREE OF SENSITIVITY AND PRECISION TO DRIVE MARKET
                    TABLE 45 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 46 NORTH AMERICA: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 47 EUROPE: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 48 ASIA PACIFIC: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 49 LATIN AMERICA: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 POLYCLONAL ANTIBODIES 
           7.3.1 ABILITY TO BE STABLE AND WITHSTAND VARIATIONS IN TEMPERATURE TO FUEL UPTAKE
                    TABLE 50 GLOBAL MARKET FOR POLYCLONAL ANTIBODIES, BY TYPE, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 51 NORTH AMERICA: MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 52 EUROPE: MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 53 ASIA PACIFIC: MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 54 LATIN AMERICA: MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 RECOMBINANT ANTIBODIES 
           7.4.1 LOW IMMUNOGENICITY AND RISING RESEARCH REPRODUCIBILITY TO DRIVE MARKET
                    TABLE 55 GLOBAL MARKET FOR RECOMBINANT ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 56 NORTH AMERICA: MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 57 EUROPE: MARKET FOR RECOMBINANT ANTIBODIES, 2021–2028 (USD MILLION)
                    TABLE 58 ASIA PACIFIC: MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 59 LATIN AMERICA: MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 OTHER CUSTOM ANTIBODIES 
          TABLE 60 OTHER CUSTOM ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 61 NORTH AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 62 EUROPE: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 63 ASIA PACIFIC: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 64 LATIN AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 CUSTOM ANTIBODY MARKET, BY SOURCE (Page No. - 102)
    8.1 INTRODUCTION 
          TABLE 65 GLOBAL MARKET, BY SOURCE, 2021–2028 (USD MILLION)
    8.2 MICE 
           8.2.1 CONVENTIONALLY PREFERRED HOSTS FOR MAB PRODUCTION TO INCREASE UPTAKE
                    TABLE 66 GLOBAL MARKET FOR MICE, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 67 NORTH AMERICA: MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 68 EUROPE: MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 69 ASIA PACIFIC: MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 70 LATIN AMERICA: MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 RABBITS 
           8.3.1 ABILITY TO GENERATE HIGH ANTIBODY DIVERSITY WITH OPTIMAL AFFINITY TO DRIVE MARKET
                    TABLE 71 GLOBAL MARKET FOR RABBITS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 72 NORTH AMERICA: MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 73 EUROPE: MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 74 ASIA PACIFIC: MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 75 LATIN AMERICA: MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 OTHER SOURCES 
          TABLE 76 GLOBAL MARKET FOR OTHER SOURCES, BY REGION, 2021–2028 (USD MILLION)
          TABLE 77 NORTH AMERICA: MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 78 EUROPE: MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 79 ASIA PACIFIC: MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 80 LATIN AMERICA: MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 CUSTOM ANTIBODY MARKET, BY APPLICATION (Page No. - 111)
    9.1 INTRODUCTION 
          TABLE 81 GLOBAL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    9.2 RESEARCH 
           9.2.1 RISING R&D ACTIVITIES FOR MAB-BASED THERAPEUTICS TO DRIVE MARKET
                    TABLE 82 GLOBAL MARKET FOR RESEARCH, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 83 NORTH AMERICA: MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 84 EUROPE: MARKET FOR RESEARCH, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 85 ASIA PACIFIC: MARKET FOR RESEARCH, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 86 LATIN AMERICA: MARKET FOR RESEARCH, BY COUNTRY,  2021–2028 (USD MILLION)
    9.3 THERAPEUTICS 
           9.3.1 GROWING USE OF MABS IN TARGETED THERAPY FOR AUTOIMMUNE DISEASES TO DRIVE MARKET
                    TABLE 87 GLOBAL MARKET FOR THERAPEUTICS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 88 NORTH AMERICA: MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 89 EUROPE: MARKET FOR THERAPEUTICS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 90 ASIA PACIFIC: MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 91 LATIN AMERICA: MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 CUSTOM ANTIBODY MARKET, BY INDICATION (Page No. - 119)
     10.1 INTRODUCTION 
             TABLE 92 GLOBAL MARKET, BY INDICATION, 2021–2028 (USD MILLION)
     10.2 ONCOLOGY 
             10.2.1 GROWING USE OF MABS IN CANCER TREATMENT TO DRIVE MARKET
                        TABLE 93 GLOBAL MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 94 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 95 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 96 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 97 LATIN AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
     10.3 INFECTIOUS DISEASES 
             10.3.1 WIDE USAGE OF ANTIBODIES IN VACCINE & THERAPEUTIC DEVELOPMENT TO DRIVE MARKET
                        TABLE 98 GLOBAL MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 99 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 100 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 101 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 102 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
     10.4 IMMUNOLOGY 
             10.4.1 RISING DEMAND FOR THERAPEUTIC ANTIBODIES IN IMMUNOLOGY TO DRIVE MARKET
                        TABLE 103 GLOBAL MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 104 NORTH AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 105 EUROPE: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 106 ASIA PACIFIC: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 107 LATIN AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
     10.5 NEUROBIOLOGY 
             10.5.1 RISING DEMAND FOR ANTIBODIES IN NEURODEGENERATIVE DISEASE TREATMENT TO DRIVE MARKET
                        TABLE 108 GLOBAL MARKET FOR NEUROBIOLOGY, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 109 NORTH AMERICA: MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 110 EUROPE: MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 111 ASIA PACIFIC: MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 112 LATIN AMERICA: MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
     10.6 CARDIOVASCULAR DISEASES 
             10.6.1 GROWING DEMAND FOR CVD BIOMARKERS TO DRIVE MARKET
                        TABLE 113 GLOBAL MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 114 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 115 EUROPE: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 116 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 117 LATIN AMERICA: MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION)
     10.7 OTHER INDICATIONS 
             TABLE 118 GLOBAL MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION)
             TABLE 119 NORTH AMERICA: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 120 EUROPE: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 121 ASIA PACIFIC: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 122 LATIN AMERICA: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
 
11 CUSTOM ANTIBODY MARKET, BY END USER (Page No. - 136)
     11.1 INTRODUCTION 
             TABLE 123 GLOBAL MARKET, BY END USER, 2021–2028 (USD MILLION)
             TABLE 124 GLOBAL MARKET, BY REGION, 2021–2028 (USD MILLION)
             TABLE 125 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 126 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 127 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 128 LATIN AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
     11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
             11.2.1 RISING NEED FOR ANTIBODIES IN BIOMARKER QUANTIFICATION TO DRIVE MARKET
                        TABLE 129 GLOBAL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 130 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 131 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 132 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 133 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
     11.3 ACADEMIC & RESEARCH INSTITUTES 
             11.3.1 GROWING INDUSTRY-ACADEMIA COLLABORATIONS AND RISING GOVERNMENT-FUNDED INITIATIVES TO DRIVE MARKET
                        TABLE 134 GLOBAL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 135 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 136 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 137 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 138 LATIN AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
     11.4 CONTRACT RESEARCH ORGANIZATIONS 
             11.4.1 ABILITY TO PROVIDE SPECIALIZED SERVICES FOR PRODUCTION OF MABS & ADCS TO SUPPORT MARKET GROWTH
                        TABLE 139 GLOBAL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 140 NORTH AMERICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 141 EUROPE: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 142 ASIA PACIFIC: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 143 LATIN AMERICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
 
12 CUSTOM ANTIBODY MARKET, BY REGION (Page No. - 149)
     12.1 INTRODUCTION 
             TABLE 144 GLOBAL MARKET, BY REGION, 2021–2028 (USD MILLION)
     12.2 NORTH AMERICA 
             FIGURE 26 NORTH AMERICA: CUSTOM ANTIBODY MARKET SNAPSHOT
             TABLE 145 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 146 NORTH AMERICA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
             TABLE 147 NORTH AMERICA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 148 NORTH AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 149 NORTH AMERICA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
             TABLE 150 NORTH AMERICA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
             TABLE 151 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 152 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.2.1 US
                        12.2.1.1 Rising research in structure-based drug design and therapeutic mAbs to drive market
                                      TABLE 153 US: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 154 US: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 155 US: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 156 US: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 157 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 158 US: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 159 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.2.2 CANADA
                        12.2.2.1 Increasing genomic research to fuel market uptake
                                      TABLE 160 CANADA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 161 CANADA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 162 CANADA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 163 CANADA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 164 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 165 CANADA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 166 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.2.3 NORTH AMERICA: RECESSION IMPACT
     12.3 EUROPE 
             TABLE 167 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 168 EUROPE: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
             TABLE 169 EUROPE: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 170 EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 171 EUROPE: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
             TABLE 172 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 173 EUROPE: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
             TABLE 174 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.1 GERMANY
                        12.3.1.1 High investments in development of ADCs to drive market
                                      TABLE 175 GERMANY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 176 GERMANY: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 177 GERMANY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 178 GERMANY: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 179 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 180 GERMANY: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 181 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.2 UK
                        12.3.2.1 Rising pharmaceutical spending and growing life sciences industry to drive market
                                      TABLE 182 UK: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 183 UK: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 184 UK: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 185 UK: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 186 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 187 UK: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 188 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.3 FRANCE
                        12.3.3.1 Growing pipeline of therapeutic mAbs coupled with rising research investments to support market growth
                                      TABLE 189 FRANCE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 190 FRANCE: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 191 FRANCE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 192 FRANCE: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 193 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 194 FRANCE: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 195 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.4 ITALY
                        12.3.4.1 Increasing research activities in proteomics & genomics to drive market
                                      TABLE 196 ITALY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 197 ITALY: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 198 ITALY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 199 ITALY: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 200 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 201 ITALY: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 202 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.5 SPAIN
                        12.3.5.1 Growing focus on advancements in personalized medicine to support market growth
                                      TABLE 203 SPAIN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 204 SPAIN: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 205 SPAIN: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 206 SPAIN: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 207 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 208 SPAIN: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 209 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.6 REST OF EUROPE
                        TABLE 210 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                        TABLE 211 REST OF EUROPE: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 212 REST OF EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 213 REST OF EUROPE: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                        TABLE 214 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 215 REST OF EUROPE: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                        TABLE 216 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.7 EUROPE: RECESSION IMPACT
     12.4 ASIA PACIFIC 
             FIGURE 27 ASIA PACIFIC: CUSTOM ANTIBODY MARKET SNAPSHOT
             TABLE 217 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 218 ASIA PACIFIC: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
             TABLE 219 ASIA PACIFIC: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 220 ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 221 ASIA PACIFIC: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
             TABLE 222 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 223 ASIA PACIFIC: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
             TABLE 224 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.1 JAPAN
                        12.4.1.1 Rising research activities for development of ADCs to drive market
                                      TABLE 225 JAPAN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 226 JAPAN: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 227 JAPAN: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 228 JAPAN: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 229 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 230 JAPAN: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 231 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.2 CHINA
                        12.4.2.1 Increasing establishment of R&D facilities to fuel uptake
                                      TABLE 232 CHINA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 233 CHINA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 234 CHINA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 235 CHINA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 236 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 237 CHINA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 238 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.3 SOUTH KOREA
                        12.4.3.1 Increasing research on therapeutic antibodies and cytokines to support market growth
                                      TABLE 239 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 240 SOUTH KOREA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 241 SOUTH KOREA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 242 SOUTH KOREA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 243 SOUTH KOREA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 244 SOUTH KOREA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 245 SOUTH KOREA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.4 INDIA
                        12.4.4.1 High pharmaceutical R&D spending to support market growth
                                      TABLE 246 INDIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 247 INDIA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 248 INDIA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 249 INDIA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 250 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 251 INDIA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 252 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.5 REST OF ASIA PACIFIC
                                TABLE 253 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                TABLE 254 REST OF ASIA PACIFIC: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 255 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 256 REST OF ASIA PACIFIC: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                TABLE 257 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 258 REST OF ASIA PACIFIC: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                TABLE 259 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.6 ASIA PACIFIC: RECESSION IMPACT
     12.5 LATIN AMERICA 
             TABLE 260 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 261 LATIN AMERICA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
             TABLE 262 LATIN AMERICA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 263 LATIN AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 264 LATIN AMERICA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
             TABLE 265 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 266 LATIN AMERICA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
             TABLE 267 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.5.1 BRAZIL
                        12.5.1.1 Utilization of therapeutic antibodies for oncology applications to support market growth
                                      TABLE 268 BRAZIL: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 269 BRAZIL: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 270 BRAZIL: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 271 BRAZIL: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 272 BRAZIL: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 273 BRAZIL: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 274 BRAZIL: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.5.2 REST OF LATIN AMERICA
                        TABLE 275 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                        TABLE 276 REST OF LATIN AMERICA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 277 REST OF LATIN AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 278 REST OF LATIN AMERICA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                        TABLE 279 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 280 REST OF LATIN AMERICA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                        TABLE 281 REST OF LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.5.3 LATIN AMERICA: RECESSION IMPACT
     12.6 MIDDLE EAST & AFRICA 
             12.6.1 INCREASING RESEARCH COLLABORATIONS AND DEVELOPING HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
                        TABLE 282 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                        TABLE 283 MIDDLE EAST & AFRICA: MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 284 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 285 MIDDLE EAST & AFRICA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                        TABLE 286 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 287 MIDDLE EAST & AFRICA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                        TABLE 288 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
 
13 COMPETITIVE LANDSCAPE (Page No. - 216)
     13.1 INTRODUCTION 
     13.2 STRATEGIES ADOPTED BY KEY CUSTOM ANTIBODY MARKET PLAYERS 
     13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
            FIGURE 28 CUSTOM ANTIBODY MARKET: REVENUE SHARE ANALYSIS OF LEADING PLAYERS
     13.4 MARKET SHARE ANALYSIS 
            FIGURE 29 GLOBAL MARKET: MARKET SHARE ANALYSIS OF LEADING PLAYERS (2022)
            TABLE 289 GLOBAL MARKET: INTENSITY OF COMPETITIVE RIVALRY
     13.5 COMPANY EVALUATION QUADRANT 
             13.5.1 STARS
             13.5.2 EMERGING LEADERS
             13.5.3 PERVASIVE PLAYERS
             13.5.4 PARTICIPANTS
                        FIGURE 30 GLOBAL CUSTOM ANTIBODY MARKET: COMPANY EVALUATION QUADRANT
     13.6 COMPANY EVALUATION QUADRANT FOR STARTUPS (2022) 
             13.6.1 PROGRESSIVE COMPANIES
             13.6.2 STARTING BLOCKS
             13.6.3 RESPONSIVE COMPANIES
             13.6.4 DYNAMIC COMPANIES
                        FIGURE 31 GLOBAL MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS (2022)
     13.7 COMPANY FOOTPRINT 
     13.8 COMPANY SERVICE FOOTPRINT 
            TABLE 290 GLOBAL CUSTOM ANTIBODY MARKET: SERVICE PORTFOLIO ANALYSIS (2022)
     13.9 COMPANY GEOGRAPHIC FOOTPRINT 
            TABLE 291 GLOBAL MARKET: GEOGRAPHIC REVENUE MIX (2022)
     13.1 KEY STRATEGIES ADOPTED BY MARKET PLAYERS 
             13.10.1 GLOBAL CUSTOM ANTIBODY MARKET: KEY DEALS (JANUARY 2020 TO JANUARY 2023)
             13.10.2 GLOBAL CUSTOM ANTIBODY MARKET: KEY EXPANSIONS (JANUARY 2020 TO JANUARY 2023)
 
14 COMPANY PROFILES (Page No. - 228)
(Business overview, Services offered, Recent developments, Other developments & MnM View)*
     14.1 KEY MARKET PLAYERS 
             14.1.1 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 292 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
                        TABLE 293 THERMO FISHER SCIENTIFIC, INC.: DEALS
             14.1.2 GENSCRIPT
                        TABLE 294 GENSCRIPT: BUSINESS OVERVIEW
                        FIGURE 33 GENSCRIPT: COMPANY SNAPSHOT (2021)
                        TABLE 295 GENSCRIPT: DEALS
             14.1.3 ABCAM PLC.
                        TABLE 296 ABCAM PLC.: BUSINESS OVERVIEW
                        FIGURE 34 ABCAM PLC.: COMPANY SNAPSHOT (2021)
                        TABLE 297 ABCAM PLC.: DEALS
             14.1.4 CELL SIGNALING TECHNOLOGY, INC.
                        TABLE 298 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
             14.1.5 BIO-RAD LABORATORIES, INC.
                        TABLE 299 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
             14.1.6 MERCK KGAA
                        TABLE 300 MERCK KGAA.: BUSINESS OVERVIEW
                        FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT (2021)
                        TABLE 301 MERCK KGAA: DEALS
             14.1.7 AGILENT TECHNOLOGIES, INC.
                        TABLE 302 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 37 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
             14.1.8 PERKINELMER, INC.
                        TABLE 303 PERKINELMER, INC.: BUSINESS OVERVIEW
                        FIGURE 38 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
             14.1.9 ROCKLAND IMMUNOCHEMICALS, INC.
                        TABLE 304 ROCKLAND IMMUNOCHEMICALS, INC.: BUSINESS OVERVIEW
                        TABLE 305 ROCKLAND IMMUNOCHEMICALS, INC.: DEALS
             14.1.10 PROMAB BIOTECHNOLOGIES, INC.
                        TABLE 306 PROMAB BIOTECHNOLOGIES, INC.: BUSINESS OVERVIEW
             14.1.11 INNOVAGEN AB
                        TABLE 307 INNOVAGEN AB: BUSINESS OVERVIEW
             14.1.12 ORIGENE TECHNOLOGIES INC.
                        TABLE 308 ORIGENE TECHNOLOGIES INC.: BUSINESS OVERVIEW
             14.1.13 BIO-TECHNE
                        TABLE 309 BIO-TECHNE: BUSINESS OVERVIEW
                        FIGURE 39 BIO-TECHNE: COMPANY SNAPSHOT (2021)
                        TABLE 310 BIO-TECHNE: DEALS
             14.1.14 CREATIVE DIAGNOSTICS
                        TABLE 311 CREATIVE DIAGNOSTICS: BUSINESS OVERVIEW
             14.1.15 SINO BIOLOGICAL, INC.
                        TABLE 312 SINO BIOLOGICAL, INC.: BUSINESS OVERVIEW
                        FIGURE 40 SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT (2021)
*Details on Business overview, Services offered, Recent developments, Other developments & MnM View might not be captured in case of unlisted companies.
     14.2 OTHER PLAYERS 
             14.2.1 RAYBIOTECH LIFE, INC.
             14.2.2 ABBIOTEC, INC.
             14.2.3 PROSCI INCORPORATED
             14.2.4 BOSTER BIOLOGICAL TECHNOLOGY
             14.2.5 CUSABIO TECHNOLOGY LLC
             14.2.6 BIOINTRON
             14.2.7 KANEKA EUROGENTEC S.A.
             14.2.8 CREATIVE BIOLABS
             14.2.9 ENVIGO
             14.2.10 IMGENEX INDIA
 
15 APPENDIX (Page No. - 270)
     15.1 DISCUSSION GUIDE 
     15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     15.3 CUSTOMIZATION OPTIONS 
     15.4 RELATED REPORTS 
     15.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the custom antibody market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. The top-down and other approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the custom antibody market. The secondary sources referred to for this research study include publications from government and private sources such as the World Health Organization (WHO), Organisation for Economic Co-operation and Development (OECD), Lens.org, Antibody Society, Antibody Technology Interest Network, Antibody Therapeutics, Pharmaceutical Research and Manufacturers of America (PhRMA), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), American Medical Association (AMA), Association of Medical Laboratory Immunologists (AMLI), National Cancer Institute (NCI), European Medicines Agency (EMA), Biotechnology and Biological Sciences Research Council (BBSRC), World Health Organization (WHO), World Bank, Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentations, Journals, Expert Interviews, MarketsandMarkets Analysis. Secondary data was collected and analyzed to arrive at the overall size of the global custom antibody market, which was then validated by primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Custom Antibody Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Top-down approach was used to estimate and validate the total size of the custom antibody market. This method was also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the custom antibody business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global custom antibody market based on the service, type,  source, application, indication, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, expansions, agreements, collaborations, and R&D activities in the global market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographic Analysis

  • Further breakdown of the Rest of Europe antibody market into respective countries
  • Further breakdown of the Rest of Asia Pacific market into respective countries
  • Further breakdown of the Rest of Latin America market into respective countries

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

Company Information

  • An additional five company profiles
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 6817
Published ON
Feb, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Custom Antibody Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback